富罗塞米德对急性左侧血栓性心力衰竭的猫的左心脏大小的急性影响
Sarah Miliaux1, Alma H Hulsman1, Sanne Hugen1
1Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 108, 3584 CM Utrecht, The Netherlands.
Animals : an open access journal from MDPI
|November 27, 2025
概括
富洛塞米德在患有充血性心力衰竭 (CHF) 的猫中迅速减少左心房的大小. 这种快速减少可以掩盖严重的左心房扩张,可能导致在兽医评估之前已经接受治疗的猫的误诊.
科学领域:
- 兽医心脏病学 兽医心脏病学
- 兽医诊断成像 在兽医诊断成像
背景情况:
- 左侧充血性心力衰竭 (CHF) 是猫急性呼吸困扰的主要原因.
- 对左心房 (LA) 尺寸的心声学评估对于区分心脏不全和其他呼吸道疾病至关重要.
- 罗塞米德对患有冠状动脉炎的猫的LA大小的影响尚未被系统地研究.
研究的目的:
- 为了研究furosemide对诊断为急性左侧心脏不全症的猫的左心脏大小的影响.
- 为了确定furosemide的使用是否会影响诊断CHF的准确性,在出现呼吸障碍的猫身上.
主要方法:
- 一项前性,观察性,多中心研究,涉及25只患有急性左侧心脏衰竭的猫.
- 护理点超声波 (POCUS) 用于测量左心房与大动脉的比率 (LA:Ao) 和最大左心房直径 (LAD).
- 测量是在入院时和furosemide注射后三小时进行的.
主要成果:
- 在furosemide使用后3小时,LA:Ao (p < 0.001),LAD (p < 0.001) 和呼吸速率 (p < 0.001) 显著降低.
- 50%的猫的呼吸速率正常化,而最大的LAD在32%的猫中正常化.
- 一只猫显示LA:Ao的正常化,表明快速但往往不完整的效果.
结论:
- 罗塞米德诱导LA大小和呼吸率的快速下降在猫的左侧CHF.
- 临床医生必须意识到,在弗洛塞米德治疗后转诊的猫可能没有显著的左心房扩张,这可能导致误诊.
- 早期服用罗塞米德可以使猫科动物中心肺风的心声图诊断复杂化.
相关概念视频
Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
Heart Failure Drugs: Diuretics
775
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
775
Mitral Regurgitation I: Introduction
392
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
392
Mitral Stenosis I: Introduction
420
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
420
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
383
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
383
Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204


